Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy
- PMID: 17582600
- DOI: 10.1002/ijc.22914
Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy
Abstract
The purpose of this study was to assess the relationship between progression-free survival (PFS) in patients treated with DFMO + PCV (procarbazine, CCNU, vincristine) chemotherapy for malignant gliomas with tumor cell ornithine decarboxylase (ODC) activity. Formalin-fixed slides were obtained for study patients with anaplastic gliomas (AGs) and glioblastoma treated on protocol DM92-035. ODC levels were measured using an antibody to ODC coupled to Alexa 647 dye (Ab-ODC-Alexa 647). Ab-ODC-Alexa 647 intensity in transgenic murine hearts of differing ODC activity was used to calculate ODC activity in tumor cell nucleoplasm. In total, tumor specimens for 31 of 114 (27%) patients treated on the AG strata and 10 patients from the GBM strata were obtained. We found that tumor ODC level heterogeneity increased with increasing tumor malignancy. In a Cox proportional hazards model, PFS was found to be inversely related to median tumor ODC activity, with an unadjusted hazard ratio for median ODC group (>3.3 vs. </=3.3 nmol/30 min/mug protein) of 5.8 (p < 0.0001); a median PFS of 522 weeks for patients with AGs with median ODC activity </= 3.3 and 31 weeks for the 8 AG and 10 glioblastoma patients with ODC activity > 3.3 nmol/30 min/mug protein. Of AG tumors in which ODC activity was evaluated, 26% had ODC levels > 3.3 nmol/30 min/mug protein. This study shows that Ab-ODC-Alexa 647 fluorescence intensity can be used as a surrogate marker of ODC biochemical activity in AGs and can predict PFS to DFMO-based chemotherapy.
(c) 2007 Wiley-Liss, Inc.
Similar articles
-
Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine.J Histochem Cytochem. 2004 Nov;52(11):1467-74. doi: 10.1369/jhc.4A6358.2004. J Histochem Cytochem. 2004. PMID: 15505341 Free PMC article.
-
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.Clin Cancer Res. 2000 Oct;6(10):3878-84. Clin Cancer Res. 2000. PMID: 11051233 Clinical Trial.
-
Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.Clin Cancer Res. 2003 Mar;9(3):981-90. Clin Cancer Res. 2003. PMID: 12631596 Clinical Trial.
-
Inhibition of ornithine decarboxylase (ODC) decreases tumor vascularization and reverses spontaneous tumors in ODC/Ras transgenic mice.Cancer Res. 2000 Oct 15;60(20):5696-703. Cancer Res. 2000. PMID: 11059762
-
Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.CNS Oncol. 2018 Apr;7(2):CNS16. doi: 10.2217/cns-2017-0031. Epub 2018 Jan 30. CNS Oncol. 2018. PMID: 29378419 Free PMC article. Review.
Cited by
-
Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells.Oncotarget. 2020 Nov 3;11(44):3933-3942. doi: 10.18632/oncotarget.27782. eCollection 2020 Nov 3. Oncotarget. 2020. PMID: 33216820 Free PMC article.
-
miR-34a Regulates Multidrug Resistance via Positively Modulating OAZ2 Signaling in Colon Cancer Cells.J Immunol Res. 2018 Aug 2;2018:7498514. doi: 10.1155/2018/7498514. eCollection 2018. J Immunol Res. 2018. PMID: 30175154 Free PMC article.
-
CNS Anticancer Drug Discovery and Development Conference White Paper.Neuro Oncol. 2015 Nov;17 Suppl 6(Suppl 6):vi1-26. doi: 10.1093/neuonc/nov169. Neuro Oncol. 2015. PMID: 26403167 Free PMC article.
-
Glioma Metabolic Feedback In Situ: A First-In-Human Pharmacodynamic Trial of Difluoromethylornithine + AMXT-1501 Through High-Molecular Weight Microdialysis.Neurosurgery. 2023 Oct 1;93(4):932-938. doi: 10.1227/neu.0000000000002511. Epub 2023 May 29. Neurosurgery. 2023. PMID: 37246885 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials